Fig. 4From: Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effectsToxicity study in healthy (non-tumour-bearing) mice. A Blood biochemical markers (n = 3) and B Hematoxylin and eosin staining of key organs, 2 weeks after receiving bosutinib-HDL NPs (20 mg/kg, IV)Back to article page